Key facts
- It has raised $14.0M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Vivo Capital, WinDigital Capital Management, Vivo Equity Investment Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Celgenyx
- ·The full record, as it builds
Funding rounds
No funding rounds for Celgenyx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Celgenyx
Manufacturer of biopharmaceutical products intended to advance gene engineering and improve human health. The company offers research-driven drug development, advanced manufacturing capabilities, and medical instruments, enabling healthcare providers and the pharmaceutical industry to access innovative therapies for enhanced patient care.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- celgenyxbio.com/
- Ownership
- Privately Held (backing)
Celgenyx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Celgenyx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Celgenyx in its N-PORT filings yet. We sweep new filings monthly.